减低剂量与标准剂量移植后环磷酰胺预防单倍体移植中移植物抗宿主病
该回顾性分析比较标准剂量(100 mg/kg)与减低剂量(80 mg/kg)移植后环磷酰胺预防单倍体移植中移植物抗宿主病,倾向性评分匹配后每组425例,两组2年总生存率、非复发死亡率及急慢性移植物抗宿主病发生率均无显著差异。
要点
- 标准剂量组与减低剂量组2年总生存率分别为55.9%与47.0%(p=0.36)。
- 2年非复发死亡率标准剂量组21.3%,减低剂量组20.5%(p=0.55)。
- 急性Ⅱ-Ⅳ级移植物抗宿主病发生率两组分别为29.2%与25.3%,无显著差异。
核心结论
- 减低剂量与标准剂量移植后环磷酰胺在主要临床结局方面相当。
研究设计与样本
- 回顾性分析,比较标准剂量移植后环磷酰胺(100 mg/kg)与减低剂量(80 mg/kg);标准剂量组969例,减低剂量组538例;因两组患者及移植特征存在显著差异,进行倾向性评分匹配,匹配后每组425例。
主要发现
- 倾向性评分匹配后,2年总生存率标准剂量组55.9%,减低剂量组47.0%(p=0.36)。
- 2年非复发死亡率累积发生率标准剂量组21.3%,减低剂量组20.5%(p=0.55)。
- 急性Ⅱ-Ⅳ级移植物抗宿主病发生率标准剂量组29.2%(95%CI 24.9-33.6),减低剂量组25.3%(95%CI 21.3-29.6);Ⅲ-Ⅳ级标准剂量组7.3%(95%CI 5.1-10.0),减低剂量组6.6%(95%CI 4.5-9.3)。
- 急性及慢性移植物抗宿主病发生率两组均无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Haploidentical haematopoietic cell transplantation (haplo-HCT) using post-transplant cyclophosphamide (PTCY) as graft-versus-host disease (GVHD) prophylaxis is the standard of care for various haematological malignancies. The original PTCY dose after haplo-HCT was 100 mg/kg, but no dose-finding studies have been performed to identify the optimal dose. We performed a retrospective analysis to compare standard-dose PTCY (100 mg/kg) with reduced-dose PTCY (80 mg/kg): 969 in the standard-dose group and 538 in the reduced-dose group. As there was a significant difference between the two groups regarding patient and transplant characteristics, we performed propensity score (PS) matching. After PS matching, 425 patients in each group were included. The probabilities of 2-year OS were 55.9% in the standard-dose group and 47.0% in the reduced-dose group (p = 0.36). The cumulative incidences of 2-year non-relapse mortality were 21.3% in the standard-dose group and 20.5% in the reduced-dose group (p = 0.55). There was no significant difference in the incidence of acute (grade II-IV 29.2% [95% CI, 24.9-33.6] vs. 25.3% [95% CI, 21.3-29.6]; grade III-IV 7.3% [95% CI, 5.1-10.0] vs. 6.6% [95% CI, 4.5-9.3]) or chronic GVHD. In conclusion, reduced- and standard-dose PTCY were comparable in terms of major clinical outcomes.
引用
- Fuji S, Sugita J, Najima Y, et al. Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation. Br J Haematol. 2023. PMID: 38037468. doi:10.1111/bjh.19228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。